Tranilast Suppresses the Disease Development of the Adjuvant- and Streptococcal Cell Wall-Induced Arthritis in Rats

DOI Web Site PubMed 被引用文献1件 参考文献51件
  • Nagate Toshiaki
    Department of Pathology, Shinshu University School of Medicine, Japan Development Research Department, R&D, Kissei Pharmaceutical Co., Ltd., Japan
  • Tamura Toru
    Development Research Department, R&D, Kissei Pharmaceutical Co., Ltd., Japan
  • Sato Fumiyasu
    Development Research Department, R&D, Kissei Pharmaceutical Co., Ltd., Japan
  • Kuroda Junji
    Development Research Department, R&D, Kissei Pharmaceutical Co., Ltd., Japan
  • Nakayama Jun
    Department of Pathology, Shinshu University School of Medicine, Japan
  • Shibata Nobuo
    Development Research Department, R&D, Kissei Pharmaceutical Co., Ltd., Japan

この論文をさがす

抄録

This study explores the effects of the anti-allergic and anti-fibrotic agent tranilast on adjuvant- and streptococcal cell wall-induced arthritis in rats, animal models of rheumatoid arthritis in humans. Tranilast (150 or 300 mg/kg, twice daily) or vehicle only was administered orally to the two arthritis models, from 17 days before sensitization. As a comparative control, methotrexate (0.1 mg/kg, once daily) was given to another group. Tranilast suppressed the increase in foot volumes, paw thicknesses, clinical scores, and histopathological scores of the ankle joints in both models dose-dependently. In addition, the fibrosis indices of the ankles were dramatically decreased by tranilast in both of the models. Compared to the effects of methotrexate, tranilast seemed to work more effectively in the streptococcal cell wall-induced arthritis model than in the adjuvant-induced arthritis model. From these observations, it can be concluded that tranilast suppresses the development of arthritis in multiple models and is potentially a novel therapeutic agent for human rheumatoid arthritis.<br>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (51)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ